Welcome to our dedicated page for Immutep SEC filings (Ticker: PRRUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for IMMUTEP LTD ORD (PRRUF) focuses on documents submitted by Immutep Limited as a foreign private issuer. The company reports under the Securities Exchange Act of 1934 and identifies Form 20-F as its primary annual report format, while using Form 6-K for current reports furnished under Rules 13a-16 or 15d-16.
Through this page, users can access Immutep Limited’s Form 6-K filings, which may include exhibits describing developments such as research collaborations. For example, one Form 6-K lists an exhibit detailing a research collaboration with the George Washington University Cancer Center to evaluate a neoadjuvant treatment referred to as efti. Such exhibits illustrate the type of operational or research information that can appear within the company’s regulatory submissions.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of each document in accessible language. Instead of reading full-length filings line by line, users can review AI-generated highlights that point to important disclosures, such as the nature of a collaboration or the context of a particular exhibit.
The filings page also provides real-time access to new submissions from the SEC’s EDGAR system, allowing investors to see when Immutep Limited furnishes additional Form 6-K reports or other documents. Users can review these filings alongside AI insights to better understand the information that Immutep Limited chooses to disclose to the U.S. market in connection with the PRRUF symbol.
IMMUTEP Ltd Chief Medical Officer Stephan Karel Gerard Winckels filed an initial ownership report showing his equity position. He directly holds 92,935 Ordinary Shares and three blocks of 221,708 performance rights each over Ordinary Shares, with vesting dates in 2026, 2027 and 2028 and an exercise price of $0.0000. The vesting of these performance rights depends on achieving specified key performance indicators and they expire in 2030.
IMMUTEP Ltd director Frederic Joseph Daniel Triebel has filed an initial statement of beneficial ownership. The filing shows direct holdings of Ordinary Shares, including 11,353,764 shares in one entry and 170,610 shares in another, which are represented by American Depositary Shares.
The filing also lists performance rights over Ordinary Shares with a zero exercise price. Footnotes state that blocks of 900,000 performance rights are scheduled to vest on December 1 of 2026, 2027 and 2028, with additional performance rights vesting only if Dr. Triebel meets specified key performance indicators at each applicable vesting date.
IMMUTEP Ltd director Dr. Russell Howard has filed an initial Form 3 showing his equity interests in the company. The filing reports performance rights over 50,000 Ordinary Shares granted on November 23, 2023, which may vest on December 1, 2026 if vesting conditions are met. Additional performance rights granted on December 2, 2025 cover 400,154 Ordinary Shares scheduled to vest on December 1, 2026, and two further tranches of 461,746 performance rights each that may vest on December 1, 2027 and December 1, 2028, all subject to specified vesting conditions. The Form 3 also reports 1,717,977 Ordinary Shares held indirectly through Regulus Star Pty Ltd.
IMMUTEP Ltd Chief Development Officer Christian Mueller filed an initial ownership report showing he directly holds 3,774,048 Ordinary Shares. This Form 3 establishes his baseline equity position as a company officer.
Mueller also holds three tranches of performance rights over 1,400,000 Ordinary Shares in total, each with a zero exercise price. Footnotes state 466,667 performance rights are scheduled to vest on December 1, 2026 and another 466,667 on December 1, 2027, while 466,666 are scheduled to vest on December 1, 2028. Vesting of the latter two tranches depends on him achieving specified key performance indicators at each applicable vesting date.
Immutep Limited reported that the Independent Data Monitoring Committee for its TACTI-004 Phase III trial in first-line non-small cell lung cancer has recommended discontinuing the study after a planned interim futility analysis. Enrolment will stop and the company will wind down the trial with patient follow up and site close out.
The study tested eftilagimod alfa in combination with pembrolizumab and chemotherapy versus pembrolizumab, chemotherapy and placebo, targeting about 756 patients across more than 150 sites in over 25 countries. Following the discontinuation, Immutep now anticipates its cash runway will extend well beyond its prior Q2 CY2027 guidance and plans to reassess capital allocation once data review is complete.
Immutep Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an exhibit describing a new research collaboration. The exhibit, titled “Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti,” indicates that the company and the George Washington University Cancer Center plan to evaluate neoadjuvant Efti in a cancer setting. This Form 6-K serves as the formal vehicle to provide that collaboration announcement to investors and regulators.